Genetic Design and Manufacturing Corporation (GDMC), a next generation design and manufacturing organization focused next-gen advanced genetic medicines, has secured US$21 Million in Series A Funding round led by private equity manager, Celadon Partners and also saw participation from WI Harper Group, SEEDS Capital, and NSG Ventures.
Read also – Israel-based Sequence Secures $5.5m Funding
The funding will be utilized to speed up the development of cutting-edge technology and enhance the efficiency of processes, in order to reduce manufacturing costs even more for partners who want to move medications from clinical trials to commercialization.
Read also – Israel-based Minute Media Acquires STN Video
CEO and Co-Founder Michael Koeris said: “With our recent funding, we aspire to cultivate stronger collaborations with more partners in the US and APAC region, working hand in hand to improve the state of healthcare and treatment for patients.”
Read also – Vivifi India Finance Raises USD 75M Series B Funding
About GDMC
Founded in 2021, Genetic Design and Manufacturing Corporation (GDMC)’s mission is to exponentially increase the availability of genetic medicines and change millions of patients’ lives. GDMC achieve this by partnering and supporting early-stage companies and investigators with innovative therapeutic modalities such as gene therapies or nucleic acids.
Read also – HashKey Capital and FTSE Russell Collaborate
Leveraging expertise in process development and manufacturing, GDMC accelerates its partners ability to bring their ideas through clinical trials and into the market.
Read also – Tokyo Century Leasing led Series A Strategic Investment in Motorist
